These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 28969604

  • 1. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
    Zhao YF, Zhu L, Liu LJ, Shi SF, Lv JC, Zhang H.
    BMC Nephrol; 2017 Sep 29; 18(1):301. PubMed ID: 28969604
    [Abstract] [Full Text] [Related]

  • 2. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.
    Ebefors K, Liu P, Lassén E, Elvin J, Candemark E, Levan K, Haraldsson B, Nyström J.
    BMC Nephrol; 2016 Apr 05; 17():40. PubMed ID: 27044423
    [Abstract] [Full Text] [Related]

  • 3. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
    Liu Y, Li H, Yu H, Wang F, Jia J, Yan T.
    BMC Nephrol; 2022 Jan 11; 23(1):25. PubMed ID: 35016642
    [Abstract] [Full Text] [Related]

  • 4. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system.
    Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H.
    Adv Otorhinolaryngol; 2011 Jan 11; 72():60-3. PubMed ID: 21865691
    [Abstract] [Full Text] [Related]

  • 5. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.
    Suzuki Y, Suzuki H, Yasutake J, Tomino Y.
    Expert Opin Biol Ther; 2015 Apr 11; 15(4):583-93. PubMed ID: 25604055
    [Abstract] [Full Text] [Related]

  • 6. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
    Tissandié E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC, Paradis V, Moreau R, Monteiro RC.
    Kidney Int; 2011 Dec 11; 80(12):1352-63. PubMed ID: 21866091
    [Abstract] [Full Text] [Related]

  • 7. Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells.
    Wang Y, Zhao MH, Zhang YK, Li XM, Wang HY.
    Clin Exp Immunol; 2004 Apr 11; 136(1):168-75. PubMed ID: 15030528
    [Abstract] [Full Text] [Related]

  • 8. Transferrin receptor engagement by polymeric IgA1 induces receptor expression and mesangial cell proliferation: role in IgA nephropathy.
    Tamouza H, Vende F, Tiwari M, Arcos-Fajardo M, Vrtovsnik F, Benhamou M, Monteiro RC, Moura IC.
    Contrib Nephrol; 2007 Apr 11; 157():144-7. PubMed ID: 17495453
    [Abstract] [Full Text] [Related]

  • 9. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.
    Reily C, Moldoveanu Z, Pramparo T, Hall S, Huang ZQ, Rice T, Novak L, Komers R, Jenkinson CP, Novak J.
    Am J Physiol Renal Physiol; 2024 May 01; 326(5):F862-F875. PubMed ID: 38511222
    [Abstract] [Full Text] [Related]

  • 10. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
    Rizk DV, Saha MK, Hall S, Novak L, Brown R, Huang ZQ, Fatima H, Julian BA, Novak J.
    J Am Soc Nephrol; 2019 Oct 01; 30(10):2017-2026. PubMed ID: 31444275
    [Abstract] [Full Text] [Related]

  • 11. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.
    Suzuki H, Moldoveanu Z, Hall S, Brown R, Julian BA, Wyatt RJ, Tomana M, Tomino Y, Novak J, Mestecky J.
    Contrib Nephrol; 2007 Oct 01; 157():129-33. PubMed ID: 17495450
    [Abstract] [Full Text] [Related]

  • 12. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells.
    Novak J, Moldoveanu Z, Renfrow MB, Yanagihara T, Suzuki H, Raska M, Hall S, Brown R, Huang WQ, Goepfert A, Kilian M, Poulsen K, Tomana M, Wyatt RJ, Julian BA, Mestecky J.
    Contrib Nephrol; 2007 Oct 01; 157():134-8. PubMed ID: 17495451
    [Abstract] [Full Text] [Related]

  • 13. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.
    Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, Mesnard L, Paubelle E, Walker F, Julian BA, Tissandié E, Tiwari MK, Camara NO, Vrtovsnik F, Benhamou M, Novak J, Monteiro RC, Moura IC.
    Kidney Int; 2012 Dec 01; 82(12):1284-96. PubMed ID: 22951891
    [Abstract] [Full Text] [Related]

  • 14. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy.
    Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, Renfrow MB, Novak L, Wyatt RJ, Novak J.
    Kidney Blood Press Res; 2008 Dec 01; 31(1):29-37. PubMed ID: 18182777
    [Abstract] [Full Text] [Related]

  • 15. Immune characteristics of renal allograft donors with mesangial IgA deposition.
    Wang Z, Zhang X, Han W, Yu G, Ying Z, Xu X, Wang M, Zhou X, Lv J, Zhang H.
    Int Immunopharmacol; 2021 Feb 01; 91():107282. PubMed ID: 33370682
    [Abstract] [Full Text] [Related]

  • 16. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
    Zachova K, Jemelkova J, Kosztyu P, Ohyama Y, Takahashi K, Zadrazil J, Orsag J, Matousovic K, Galuszkova D, Petejova N, Mestecky J, Raska M.
    J Am Soc Nephrol; 2022 May 01; 33(5):908-917. PubMed ID: 35115327
    [Abstract] [Full Text] [Related]

  • 17. Synergistic effect of mesangial cell-induced CXCL1 and TGF-β1 in promoting podocyte loss in IgA nephropathy.
    Zhu L, Zhang Q, Shi S, Liu L, Lv J, Zhang H.
    PLoS One; 2013 May 01; 8(8):e73425. PubMed ID: 24023680
    [Abstract] [Full Text] [Related]

  • 18. Integrin α1/β1 and α2/β1 as a receptor for IgA1 in human glomerular mesangial cells in IgA nephropathy.
    Kaneko Y, Otsuka T, Tsuchida Y, Gejyo F, Narita I.
    Int Immunol; 2012 Apr 01; 24(4):219-32. PubMed ID: 22298882
    [Abstract] [Full Text] [Related]

  • 19. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
    Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J.
    J Clin Invest; 2009 Jun 01; 119(6):1668-77. PubMed ID: 19478457
    [Abstract] [Full Text] [Related]

  • 20. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
    Gomes MM, Suzuki H, Brooks MT, Tomana M, Moldoveanu Z, Mestecky J, Julian BA, Novak J, Herr AB.
    Biochemistry; 2010 Jul 13; 49(27):5671-82. PubMed ID: 20507092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.